Monitor for Clinical Trial Application submission later this year and further tranche draws under the $100M facility. The $2M raised provides limited runway; additional financing is likely needed before Phase 1b data. Dilution risk from Series C conversion and common stock issuable (33M shares) is material.
Price Chart
Executive Summary
Propanc Biopharma reported a Q3 net loss of $6.36M (vs $54.07M in Q3 2025), with zero revenue. The company highlighted a $100M private placement facility (initial $2M received), reduced convertible notes to $55K, and progress toward a Phase 1b FIH study for PRP. As a pre-revenue clinical-stage biotech, the narrower loss reflects lower noncash compensation, not operational improvement.
Key Financial Metrics
Key Facts
- Q3 net loss of $6.36M vs $54.07M in Q3 2025; net loss per share $(0.28) vs $(12.50)
- Zero revenue; pre-revenue clinical-stage biotech
- Entered $100M private placement facility; received $2M initial investment via Series C Convertible Preferred Stock
- Convertible notes reduced to $55K from $538K at June 30, 2025
- Cash at quarter-end $443,702; subsequently received $0.5M tranche from Series C facility
- Executed service agreement with FyoniBio for PK assay validation ahead of Phase 1b FIH study
- Multi-year research collaboration with Universities of Jaén and Granada for anti-aging and cancer IP
Financial Impact
Narrower net loss of $6.36M vs $54.07M YoY driven by lower noncash compensation; no revenue; cash burn remains high relative to $443K cash balance
Risk Factors
- Pre-revenue with high cash burn; $443K cash insufficient to fund operations without additional draws
- Dilution from 33M common shares issuable and Series C Convertible Preferred Stock conversion
- Phase 1b FIH study may fail to demonstrate safety or efficacy
- Nasdaq continued listing standards risk given low market cap ($2M)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3295851 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | Press Release | $0.2800 | awaiting T+5 | — | $2.35 (+738.75%) |
Oct 5, 2026 21d ago | S-1 | $0.4913 $0.4125 | ▲ +16.04% | ▲ +15.90% | $2.35 (−378.02%) |
Sep 29, 2026 28d ago | Press Release | $0.5123 $0.4913 | ▼ −4.10% | ▼ −6.05% | $2.35 (+358.42%) |
Aug 18, 2026 10w ago | Press Release | $1.16 $1.13 | ▼ −2.59% | ▼ −2.39% | $2.35 (+102.46%) |
Jul 14, 2026 14w ago | 8-K | $1.63 $1.44 | ▼ −11.66% | ▼ −10.68% | $2.35 (+44.08%) |
May 19, 2026 23w ago | Press Release | $2.01 $1.62 | ▼ −19.20% | ▼ −21.45% | $2.35 (+17.13%) |
May 15, 2026 23w ago | Press Release | $1.70 $1.76 | ▲ +3.53% | ▲ +2.57% | $2.35 (+38.15%) |
May 13, 2026 23w ago | Press Release | $1.83 $1.73 | ▼ −5.34% | ▼ −4.62% | $2.35 (+28.51%) |
Apr 21, 2026 27w ago | EFFECT | $2.83 $2.65 | ▼ −6.28% | ▼ −7.36% | $2.35 (−16.94%) |
Mar 24, 2026 31w ago | Press Release | $2.77 $2.65 | ▼ −4.33% | ▼ −3.91% | $2.35 (−15.22%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers